Pharmacologic prevention of coronary artery disease. What do clinical trials show?
Can atherosclerotic heart disease be halted or even reversed by aggressive pharmacologic therapy? Studies in recent years have shown that small amounts of plaque regression may be accompanied by considerable reduction in the rate of clinical cardiac events. In this article, the authors examine the results of important studies on lipid-lowering agents, low-dose aspirin, estrogen replacement, and calcium antagonists.
Milani
R V
RV
Department of Internal Medicine, Ochsner Medical Institutions, New Orleans, LA 70121, USA. RMilani@ochsner.org
Lavie
C J
CJ
D001241:Aspirin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*
D004967:Estrogens; D000960:Hypolipidemic Agents; D001241:Aspirin